MRPL3

Across TCGA pan-cancer cohorts, MRPL3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MRPL3 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MRPL3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MRPL3 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where MRPL3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.485	1.000	.036	9	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	8	view →
LSCC	DFS	Quartile	II,III,IV	0.248	0.811	.038	3	view →
HNSC	DFS	Median	II,III,IV	0.982	0.910	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MRPL3–CCRCC (OS)

Open the CCRCC breakdown →